strong operational performance+-+-York-based Pfizer Inc.+-+-Wall Street expectations+-+-net income+-+-biggest U.S. drugmaker+-+-first-quarter net income+-+-fellow drugmaker Allergan+-+-lower-cost biotech drugs+-+-infusion device maker+-+-currency exchange rates+-+-Hospira cost savings+-+-initial cost savings+-+-legacy Hospira operations+-+-injectable drugs+-+-injectable drugmaker+-+-lower tax+-+-higher sales+-+-financial forecasts+-+-business outlook+-+-global market+-+-new class+-+-Established businesses+-+-key driver+-+-excellent progress+-+-Ian Read+-+-chief executive+-+-earnings-per-share guidance+-+-cents+-+-percent+-+-deal+-+-revenue+-+-remainder+-+-chairman+-+-taxes+-+-company+-+-record+-+-headquarters+-+-paper+-+-Ireland+-+-changes+-+-purchase+-+-Tuesday+-+-biosimilars+-+-Plc+-+-board+-+-statement